MindBio Therapeutics Corp.
Research MindBio Therapeutics Corp. (WF60) on Bullrun: market cap EUR 728.31K. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerWF60
- ExchangeF
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 728.31K
- Financial periodQ1 2026
- RevenueAUD 0
- Net income-AUD 2.06M
- Free cash flow-AUD 621.73K
Valuation Snapshot
latest market cap is EUR 728.31K.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 0 | -AUD 6.01M | -AUD 1.08M | n/a | n/a | AUD 420.40K | AUD 2.24M | -AUD 1.96M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 728.31K | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About MindBio Therapeutics Corp.
MindBio Therapeutics Corp., together with its subsidiaries, engages in researching, developing, and testing psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. Its lead drug candidate is MB22001, a form of lysergic acid diethylamide in Phase 2A trials. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is MindBio Therapeutics Corp.'s market cap?
MindBio Therapeutics Corp.'s market capitalization is EUR 728.31K.
What does MindBio Therapeutics Corp. do?
MindBio Therapeutics Corp., together with its subsidiaries, engages in researching, developing, and testing psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. Its lead drug candidate is MB22001, a form of lysergic acid diethylamide in Phase 2A trials.